Percutaneous cryoablation of chondroblastoma and osteoblastoma in pediatric patients

BackgroundTo review the safety and efficacy of percutaneous cryoablation for the treatment of chondroblastoma and osteoblastoma in the pediatric and adolescent population.Materials and methodsA retrospective review from 2016 to 2020 was performed to evaluate clinical and imaging response to percutaneous cryoablation in 11 symptomatic patients with diagnosis of chondroblastoma and osteoblastoma treated from two pediatric hospitals with at least 12-month follow-up. Technical success (correct needle placement and potential full coverage of the tumor with the planned ablation zone) and clinical success (relief of the symptoms) were evaluated. The primary objective was to alleviate pain related to the lesion(s). Immediate and late complications were recorded. Patients were followed in clinic and with imaging studies such as MRI or CT for a minimum of 6 months.ResultsA total of 11 patients were included (mean 14 years, age range 9-17; male n=8). Diagnoses were osteoblastoma (n=4) and chondroblastoma (n=7). Locations were proximal humerus (n=1), femur condyle (n=1), and proximal femur (n=1) tibia (n=3), acetabulum (n=3), thoracic vertebra (n=1) and lumbar vertebra (n=1). Cryoablation was technically successful in all patients. Clinical success (cessation of pain) was achieved in all patients. No signs of recurrence were observed on imaging follow-up in any of the patients. One of the patients developed periprocedural right L2-L3 transient radiculopathy as major immediate complication.ConclusionsPercutaneous image-guided cryoablation can be considered potentially safe and effective treatment for chondroblastoma and osteoblastoma in children and adolescents.

Automated summary

Percutaneous cryoablation is potentially safe and effective for treating chondroblastoma and osteoblastoma in children and adolescents, with technical and clinical success achieved in all patients, and no evidence of recurrence on imaging follow-up for at least 6 months.